Patents Assigned to Factor Bioscience Inc.
-
Patent number: 12227768Abstract: The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.Type: GrantFiled: October 3, 2022Date of Patent: February 18, 2025Assignee: Factor Bioscience Inc.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 12227757Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.Type: GrantFiled: August 5, 2022Date of Patent: February 18, 2025Assignee: Factor Bioscience Inc.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 12201675Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules, including cells present in vivo. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.Type: GrantFiled: September 6, 2019Date of Patent: January 21, 2025Assignee: Factor Bioscience Inc.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 12006508Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.Type: GrantFiled: June 25, 2020Date of Patent: June 11, 2024Assignee: Factor Bioscience Inc.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 11904023Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.Type: GrantFiled: September 11, 2020Date of Patent: February 20, 2024Assignee: Factor Bioscience Inc.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 11814333Abstract: The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.Type: GrantFiled: December 16, 2021Date of Patent: November 14, 2023Assignee: Factor Bioscience Inc.Inventors: Matthew Angel, Franklin Kostas, Christopher Rohde
-
Patent number: 11708586Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.Type: GrantFiled: June 26, 2020Date of Patent: July 25, 2023Assignee: Factor Bioscience Inc.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 11692203Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.Type: GrantFiled: June 26, 2020Date of Patent: July 4, 2023Assignee: Factor Bioscience Inc.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 11492600Abstract: The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.Type: GrantFiled: September 6, 2019Date of Patent: November 8, 2022Assignee: Factor Bioscience Inc.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 11466293Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.Type: GrantFiled: September 11, 2019Date of Patent: October 11, 2022Assignee: Factor Bioscience Inc.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 11339409Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.Type: GrantFiled: October 16, 2019Date of Patent: May 24, 2022Assignee: FACTOR BIOSCIENCE INC.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 11339410Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.Type: GrantFiled: October 16, 2019Date of Patent: May 24, 2022Assignee: FACTOR BIOSCIENCE INC.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 11332758Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.Type: GrantFiled: October 17, 2019Date of Patent: May 17, 2022Assignee: FACTOR BIOSCIENCE INC.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 11332759Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.Type: GrantFiled: October 18, 2019Date of Patent: May 17, 2022Assignee: FACTOR BIOSCIENCE INC.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 11241505Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.Type: GrantFiled: February 16, 2016Date of Patent: February 8, 2022Assignee: FACTOR BIOSCIENCE INC.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 11242311Abstract: The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.Type: GrantFiled: July 16, 2020Date of Patent: February 8, 2022Assignee: FACTOR BIOSCIENCE INC.Inventors: Matthew Angel, Franklin Kostas, Christopher Rohde
-
Patent number: 10982229Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.Type: GrantFiled: May 7, 2020Date of Patent: April 20, 2021Assignee: Factor Bioscience Inc.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 10894092Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.Type: GrantFiled: June 14, 2019Date of Patent: January 19, 2021Assignee: Factor Bioscience Inc.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 10888627Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.Type: GrantFiled: June 14, 2019Date of Patent: January 12, 2021Assignee: Factor Bioscience Inc.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 10829738Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.Type: GrantFiled: April 24, 2020Date of Patent: November 10, 2020Assignee: Factor Bioscience Inc.Inventors: Matthew Angel, Christopher Rohde